Plain-English translation of NCT07198841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether IBI351, a new medication, works better when combined with cetuximab β to treat advanced lung cancer that hasn't been treated before. The study focuses specifically on people whose cancer has a genetic change called KRAS G12C. Researchers want to see how well this medication combination shrinks tumors and how safe it is.
Advanced lung cancer can be hard to treat, especially when it has this specific genetic mutation. This trial exists to find out whether this new medication combination could help people whose cancer has this genetic change, offering them a potentially more effective treatment option.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication combination regularly at a hospital or clinic. Treatment continues as long as the cancer is responding and you are tolerating the medication well, or until the cancer starts growing again. Doctors will monitor you closely with scans and blood tests to track how well the treatment is working and watch for any side effects. The study involves 48 participants across multiple centers.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China